The global high-throughput screening market size was estimated to be USD 25.89 billion in 2023 and is expected to reach at USD 87.79 billion by 2034 with a CAGR of 11.74% during the forecast period 2024-2034. Surge in number of high-throughput screening (HTS) facilities, freely availability of high-throughput screening facilities, growing number of drug targets for screening, rising investments by government & research institutes, increasing technological advancements in high-throughput screening, growing usage in universities and research centers, rising focus on development of advanced platforms, and increasing launch of innovative high-end solutions for high-throughput screening (HTS) are some of the primary elements driving market expansion.
Increasing in launch of innovative high-end solutions for high-throughput screening (HTS) is predicted to boost the market growth during the forecast period. High throughput screening, often referred to as high content screening (HCS), is primarily employed for conducting a range of genetic, chemical, and pharmacological examinations that support the drug discovery journey, spanning from initial drug development to drug trials and additional investigations into drug interactions. This methodology entails the use of control software, diverse liquid handling equipment, and various detectors, all of which contribute to the swift identification of active compounds, genetic interactions, and other biomolecular interactions. For instance, in February 2022, Bruker Corporation has introduced the timsTOF MALDI PharmaPulse (timsTOF MPP) system, an innovative high-level solution for comprehensive, unbiased high-throughput screening (HTS) and ultra-high-throughput screening (uHTS) using label-free mass spectrometry.
By product, consumables was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to increasing adoption of reagents & assay kits in HTS techniques, rising research & development activities, and growing investment by government for research. Additionally, software & services is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of advanced data processing software for automation of different liquid handling systems and surge in launch of innovative & technologically advanced platform. For instance, in February 2023, Agilent Technologies, Inc. introduced an on-deck thermal cycler that seamlessly integrates with the Agilent Bravo NGS automated liquid handling platform.
By technology, ultra-high-throughput screening was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to rising need for novel treatments for various illnesses, surge in technological advancements, and growing focus on development of software & chemical libraries. Additionally, cell-based assays is predicted to grow at fastest CAGR during the forecast period owing to the rising funding from governments & other research institutes to adopt newer technologies and faster data processing software and increasing launch of advanced software. For instance, in July 2022, Evotech Technologies has unveiled the 'Opera' cell analyzer, designed to swiftly perform high-content analysis of drug effectiveness at a sub-cellular level.
By application, drug discovery was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to surge in number of clinical trials, growing research & development expenditures, increasing adoption of automated high-throughput screening & ultra-high throughput screening techniques, and rising focus on development of innovative product. For instance, in August 2022, Molbio Diagnostics has introduced a novel test that enables distinguishing between HIV 1 and HIV 2, providing viral load results in under an hour. Additionally, chemical biology is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of advanced technologies and rising focus on development of chemical libraries.
By end-user, pharmaceutical & biotechnology firms was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to rising development of novel molecules for the treatment of various chronic conditions, increasing need for rapid & precise screening of target molecules, growing adoption of automated high-throughput screening techniques, surge in pharmaceutical investment on research & development activities, and rising technological advancements. Additionally, academia & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, rising focus on development of novel products, increasing adoption of advanced technologies in the field of research, and surge in investment by major market players. For instance, in January 2022, As per the Danaher Full Year reports, Danaher Corporation allocated $1,742 million to research and development in 2021, in contrast to the $1,348 million invested in 2020.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising adoption of high-throughput screening, growing research & development expenditure, increasing advancements in combinatorial chemistry & genomics, and surge in product launches. For instance, in February 2023, PerkinElmer, Inc., a renowned global leader dedicated to innovation in support of a healthier world, has introduced the EnVision® Nexus™ system. This advanced multimode plate reader represents the company's swiftest and most responsive offering to date, specifically engineered to cater to the rigorous demands of high-throughput screening (HTS) applications and to expedite drug discovery initiatives. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in technological advancements, rise in drug discovery techniques using 3D-cell cultures, growing efforts for the development of new pharmaceutical molecule, and increasing launch of advanced systems. For instance, in November 2022, Particle Works has introduced the Automated Library Synthesis (ALiS) System, a pioneering platform designed for the automation and high-throughput screening of lipid nanoparticle (LNP) formulations and mRNA candidates during the initial phases of drug development.
Increasing in launch of innovative high-end solutions for high-throughput screening (HTS) is predicted to boost the market growth during the forecast period. High throughput screening, often referred to as high content screening (HCS), is primarily employed for conducting a range of genetic, chemical, and pharmacological examinations that support the drug discovery journey, spanning from initial drug development to drug trials and additional investigations into drug interactions. This methodology entails the use of control software, diverse liquid handling equipment, and various detectors, all of which contribute to the swift identification of active compounds, genetic interactions, and other biomolecular interactions. For instance, in February 2022, Bruker Corporation has introduced the timsTOF MALDI PharmaPulse (timsTOF MPP) system, an innovative high-level solution for comprehensive, unbiased high-throughput screening (HTS) and ultra-high-throughput screening (uHTS) using label-free mass spectrometry.
By product, consumables was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to increasing adoption of reagents & assay kits in HTS techniques, rising research & development activities, and growing investment by government for research. Additionally, software & services is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of advanced data processing software for automation of different liquid handling systems and surge in launch of innovative & technologically advanced platform. For instance, in February 2023, Agilent Technologies, Inc. introduced an on-deck thermal cycler that seamlessly integrates with the Agilent Bravo NGS automated liquid handling platform.
By technology, ultra-high-throughput screening was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to rising need for novel treatments for various illnesses, surge in technological advancements, and growing focus on development of software & chemical libraries. Additionally, cell-based assays is predicted to grow at fastest CAGR during the forecast period owing to the rising funding from governments & other research institutes to adopt newer technologies and faster data processing software and increasing launch of advanced software. For instance, in July 2022, Evotech Technologies has unveiled the 'Opera' cell analyzer, designed to swiftly perform high-content analysis of drug effectiveness at a sub-cellular level.
By application, drug discovery was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to surge in number of clinical trials, growing research & development expenditures, increasing adoption of automated high-throughput screening & ultra-high throughput screening techniques, and rising focus on development of innovative product. For instance, in August 2022, Molbio Diagnostics has introduced a novel test that enables distinguishing between HIV 1 and HIV 2, providing viral load results in under an hour. Additionally, chemical biology is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of advanced technologies and rising focus on development of chemical libraries.
By end-user, pharmaceutical & biotechnology firms was the highest revenue-grossing segment in the global high-throughput screening market in 2023 owing to rising development of novel molecules for the treatment of various chronic conditions, increasing need for rapid & precise screening of target molecules, growing adoption of automated high-throughput screening techniques, surge in pharmaceutical investment on research & development activities, and rising technological advancements. Additionally, academia & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, rising focus on development of novel products, increasing adoption of advanced technologies in the field of research, and surge in investment by major market players. For instance, in January 2022, As per the Danaher Full Year reports, Danaher Corporation allocated $1,742 million to research and development in 2021, in contrast to the $1,348 million invested in 2020.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising adoption of high-throughput screening, growing research & development expenditure, increasing advancements in combinatorial chemistry & genomics, and surge in product launches. For instance, in February 2023, PerkinElmer, Inc., a renowned global leader dedicated to innovation in support of a healthier world, has introduced the EnVision® Nexus™ system. This advanced multimode plate reader represents the company's swiftest and most responsive offering to date, specifically engineered to cater to the rigorous demands of high-throughput screening (HTS) applications and to expedite drug discovery initiatives. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in technological advancements, rise in drug discovery techniques using 3D-cell cultures, growing efforts for the development of new pharmaceutical molecule, and increasing launch of advanced systems. For instance, in November 2022, Particle Works has introduced the Automated Library Synthesis (ALiS) System, a pioneering platform designed for the automation and high-throughput screening of lipid nanoparticle (LNP) formulations and mRNA candidates during the initial phases of drug development.
Segmentation: High-Throughput Screening Market Report 2022 - 2033
High-Throughput Screening Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Instruments
- Software & Services
- Consumables
High-Throughput Screening Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Cell-Based Assays
- Lab-On-A-Chip
- Ultra-High-Throughput Screening
- Label-Free Technology
High-Throughput Screening Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Biochemical Screening
- Drug Discovery
- Cell- & Organ-Based Screening
- Chemical Biology
High-Throughput Screening Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Academia & Research Institutes
- Pharmaceutical & Biotechnology Firms
- Contract Research Organizations
High-Throughput Screening Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. High-Throughput Screening Market: Product Estimates & Trend Analysis
8. High-Throughput Screening Market: Technology Estimates & Trend Analysis
9. High-Throughput Screening Market: Application Estimates & Trend Analysis
10. High-Throughput Screening Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America High-Throughput Screening Market
13. Europe Global High-Throughput Screening Market
14. Asia Pacific Global High-Throughput Screening Market
15. Latin America Global High-Throughput Screening Market
16. MEA Global High-Throughput Screening Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Bio-Rad Laboratories Inc.
- Agilent Technologies Inc.
- Tecan Group Ltd
- Danaher Corporation
- Axxam SpA
- Beckman Coulter Inc.
- Thermo Fisher Scientific Inc.
- PerkinElmer Inc.
- GE Healthcare
- Merck KGaA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 25.89 Billion |
| Forecasted Market Value ( USD | $ 87.79 Billion |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
